MicroRNA-200a inhibits epithelial-mesenchymal transition in human XXXX cell line.

@entity522 @entity23106 @entity5962 @entity98 @entity2277 @entity157
OBJECTIVE: Our study investigated the role of @entity23106 and its molecular @entity157 ( @entity157 ) cells. METHODS: An inhibitor of @entity23106 was transiently transfected into the @entity157 cell line, MHCC-97L. The effect of this transfection on mRNA levels of epithelial-mesenchymal transition (EMT)-related genes was measured by fluorescence-based quantitative real-time polymerase chain reaction (qRT-PCR). Further, protein levels of EMT-related genes, cell proliferation and apoptosis-related markers were assessed by Western blot analysis in these transfected cells. @entity98 and wound-healing assay were used to evaluate the proliferation and migration of MHCC-97L cells in presence and in absence of @entity23106 inhibitor. RESULTS: Compared with miR-NC control group, qRT-PCR results in anti- @entity23106 group revealed a significant reduction in the mRNA levels of @entity5962 , with a concomitant increasing in @entity2277 mRNA level (all P < 0.05). Western blot results showed higher @entity5962 and @entity522 protein expressions in anti- @entity23106 group compared to miR-NC group (P < 0.05). In addition, @entity2277 and Ki-67 protein expression was found sharply decreased in anti- @entity23106 group compared to miR-NC group (P < 0.05). Consistent with this, wound-healing and @entity98 assay showed that migration and proliferation capacity of MHCC-97L cells in anti- @entity23106 group is significantly increased compared with miR-NC group (both P < 0.05). CONCLUSION: Our study reveals an important role of @entity23106 in inhibiting EMT, proliferation and migration in @entity157 cells, suggesting the possibility of @entity23106 -based therapeutics in @entity157 .
